In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We discuss the current literature on mTOR in SARS-CoV-2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of coronavirus disease 2019.
Bibliographical noteFunding Information:
This study was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient‐Centered Outcomes Research Institute (PCORI), grant K12HS026379 (Christopher J. Tignanelli), the Minnesota Learning Health System Mentored Training Program (MH‐LHS), M Health Fairview Institutional Funds (Carolyn T. Bramante), the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (Carolyn T. Bramante), the National Heart, Lung, Blood Institute T32HL07741 (Nicholas E. Ingraham), COVID‐19 rapid response grant UM 2020‐2231. The work was supported by the University of Minnesota Institute for Engineering in Medicine Medtronic Professorship held by David J. Odde, and a COVID‐19 rapid response grant to David J. Odde from the University of Minnesota Medical School, as well as the National Institute of Health, grant U54‐CA210190 (David J. Odde).